Clinical Trials Logo

Filter by:
NCT ID: NCT02599701 Terminated - Sleep Clinical Trials

Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men

Start date: September 2015
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to evaluate the effects of gabapentin in sleep polysomnography parameters and in nocturnal secretion of endogenous hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary-gonadal (HPG) and somatotropic axes hormones and basal IGF-1 in older men.

NCT ID: NCT02598297 Terminated - Clinical trials for Myelofibrosis With High Molecular Risk Mutations

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.

ReTHINK
Start date: February 3, 2016
Phase: Phase 3
Study type: Interventional

Myelofibrosis patients with high molecular risk mutations have an intrinsically aggressive disease with increased risk of leukemic transformation and reduced overall survival. As there are no therapies currently established in the subset of high molecular risk patients with early myelofibrosis, the study aimed to evaluate ruxolitinib in this patient population.

NCT ID: NCT02595814 Terminated - Acute Heart Failure Clinical Trials

Global Non-interventional Heart Failure Disease Registry

REPORT-HF
Start date: July 23, 2014
Phase:
Study type: Observational [Patient Registry]

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

NCT ID: NCT02593851 Terminated - Clinical trials for Respiratory Syncytial Virus Infections

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

Start date: December 4, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacokinetics, safety, tolerability, antiviral activity, and impact on the clinical course of Respiratory Syncytial Virus (RSV) infection after multiple oral doses of JNJ-53718678 at different doses and/or dosing regimens in infants (greater than [>] 1 month to less than or equal to [<=] 24 months of age) who are hospitalized with RSV infection.

NCT ID: NCT02589314 Terminated - Clinical trials for Chronic Periodontitis

Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2

Start date: November 2015
Phase:
Study type: Observational

This study will evaluate if periodontal mechanical treatment is capable to alter immunological and genetical parameters related to systemic health in patients with chronic periodontitis ant diabetes type 2.

NCT ID: NCT02581397 Terminated - Cough Clinical Trials

Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough

Transpulmin
Start date: May 5, 2015
Phase: Phase 3
Study type: Interventional

This study evaluates the non-inferiority of Suppository Transpulmin and Suppository Guaiacol compared to Transpulmin Syrup in the treatment of cough with secretion of infectious origin in children between two and six years old. One third of participants will receive Suppository Transpulmin, the other one third will receive Suppository Guaiacol and the last one third will receive Transpulmin Syrup.

NCT ID: NCT02574156 Terminated - Hyperglycemia Clinical Trials

Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial

CHyCS
Start date: January 1, 2017
Phase: Phase 3
Study type: Interventional

The investigators aim to study the impact of a strategy of a intensive glycemic control in patients undergoing cardiac surgery.

NCT ID: NCT02532660 Terminated - Depression Clinical Trials

Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode

LABCATTCJUSS
Start date: July 2, 2018
Phase: Phase 3
Study type: Interventional

Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram + Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score measured by the Hamilton Scale (HAM-D).

NCT ID: NCT02527343 Terminated - Clinical trials for Familial Partial Lipodystrophy

The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy

Start date: December 28, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of volanesorsen given for 52 weeks in a randomized treatment (RT) period in participants with familial partial lipodystrophy (FPL). Following the randomized treatment period, participants who did not enter the open-label extension (OLE) period went straight to the 13-week post-treatment (PT) follow-up period and participants who were entered in the OLE period continued to receive volanesorsen for another 52 weeks (Weeks 53 to 104). Following the Week 104 visit of the OLE period, participants had an option of continued dosing for up to an additional 52 weeks (Week 105 to 156). Participants who did not enter the OLE period went straight to a 13-week post-treatment follow-up period. Following the Week 104 OLE period, participants were entered a 13-week post-treatment follow-up period, if they did not choose the option for continued dosing.

NCT ID: NCT02479386 Terminated - Geographic Atrophy Clinical Trials

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Proxima A
Start date: June 24, 2015
Phase:
Study type: Observational

This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. This is a global, prospective, multicenter, epidemiologic study enrolling participants with GA secondary to AMD. The study visits are scheduled to occur every 6 months. The anticipated duration of the study is up to 48 months. There is a planned interim analysis around the 2-year time window for the study.